Generation of a Vero-Based Packaging Cell Line to Produce SV40 Gene Delivery Vectors for Use in Clinical Gene Therapy Studies

摘要

Replication-defective (RD) recombinant simian virus 40 (SV40)-based gene delivery vectors hold a great potential for clinical applications because of their presumed non-immunogenicity and capacity to induce immune tolerance to the transgene products in humans. However, the clinical use of {SV40} vectors has been hampered by the lack of a packaging cell line that produces replication-competent (RC) free {SV40} particles in the vector production process. To solve this problem, we have adapted the current {SV40} vector genome used for the production of vector particles and generated a novel Vero-based packaging cell line named SuperVero that exclusively expresses the {SV40} large T antigen. SuperVero cells produce similar numbers of {SV40} vector particles compared to the currently used packaging cell lines, albeit in the absence of contaminating {RC} {SV40} particles. Our unique {SV40} vector platform named {SVac} paves the way to clinically test a whole new generation of SV40-based therapeutics for a broad range of important diseases.